Connecting you to the knowledge you need

A Mayo Clinic podcast hosted by Bobbi Pritt, M.D., sharing knowledge and advances in testing, laboratory science, and the people who make it all happen behind the scenes. Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser or listen from your mobile device on a preferred listening app.

Bobbi Pritt, M.D.

Follow along on Twitter: @ParasiteGal

Assay finds genetic cause of low bile flow: Devin Oglesbee, Ph.D.
December 26, 2023

Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.
The Past, Present, and Future of Diagnostics: Bill Morice, M.D., Ph.D.
December 21, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to reflect on key moments from 2023 and to discuss what may lie ahead in 2024.
Assay identifies biomarker of autoimmune encephalitis subtype: Andrew McKeon, M.B., B.Ch., M.D.
December 19, 2023

Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' GABA-A receptor antibody assay aids diagnosis of this serious but treatable condition.
Milestone Treatments for Sickle Cell Disease: Bill Morice, M.D., Ph.D.
December 14, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the U.S. Food and Drug Administration’s (FDA) recent approval of two gene therapies for sickle cell disease.
Panel offers proactive drug monitoring for IBD: Maria Willrich, Ph.D., and Melissa Snyder, Ph.D.
December 12, 2023

Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients' response to infliximab and adalimumab.
Comments on the FDA’s Proposed Rule: Bill Morice, M.D., Ph.D.
December 7, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the U.S. Food and Drug Administration’s (FDA) proposed rule on laboratory-developed tests (LDTs) and the comments Mayo Clinic submitted to the FDA.
Protecting Against Winter Respiratory Viruses: Bill Morice, M.D., Ph.D.
November 30, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss current respiratory virus activity and the importance of staying up-to-date on preventive vaccines.

Congressional and Federal Updates: Bill Morice, M.D., Ph.D.
November 23, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the one-year delay to clinical laboratory payment cuts recently passed by Congress and the importance of responding to the FDA’s proposed rule on laboratory developed tests.
Perspectives from Washington, D.C.: Bill Morice, M.D., Ph.D.
November 16, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss key takeaways from Dr. Morice’s recent visit in Washington, D.C.

RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D.
November 14, 2023

Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Safeguards for AI in Healthcare: Bill Morice, M.D., Ph.D.
November 9, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss strategies for responsible innovation and how new standards for artificial intelligence (AI) safety will impact laboratory medicine and diagnostics.
A Possible Cure for Sickle Cell Disease: Bill Morice, M.D., Ph.D.
November 2, 2023

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the recent news of a possible cure for sickle cell disease, as well as gene editing therapies and their impact on the laboratory.

View MoreView Less